详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.

146| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Peking University People’s Hospital, Beijing, China, [2]Gachon University Gil Hospital, Incheon, Korea, [3]National Taiwan University Hospital, Taipei, Taiwan, [4]Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, [5]Chonnam National University Hwasun Hospital, Hwasungun, Jeonnam, Korea, [6]West China Hospital of Sichuan University, Chengdu, China, [7]Seoul National University Hospital, [8]Sungkyunkwan University, Samsung Medical Centre, Seoul, Korea, [9]Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China, [10]National Cancer Centre, Gyeonggi-do, Korea, [11]Beijing Chao-Yang Hospital, Beijing, China, [12]The Catholic University of Korea, Seoul, [13]Hallym University Sacred Heart Hospital, Anyang, [14]Seoul National University Bundang Hospital, Seongnam, [15]Chonbuk National University Hospital, Jeonju, Korea, [16]Celgene Corporation, Summit, NJ, USA, [17]Hospital University Centre (CHU), Bordeaux, [18]Service des Maladies du Sang, Hoˆpital Claude Huriez, Lille, France

出处：

DOI：

ISSN：

关键词： lenalidomide multiple myeloma transplant-ineligible newly diagnosed Asia

摘要：

The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Given genetic differences between Asian and Western populations, this subanalysis of the FIRST trial examined the safety and efficacy of Rd (given continuously or for 18 cycles [Rd18]) and MPT (melphalan, prednisone, thalidomide) in 114 Asian patients from Mainland China, South Korea and Taiwan. Efficacy and safety with Rd continuous in Asian patients were consistent with those in the overall study population. The overall response rates were 77·8% for Rd continuous, 57·5% for MPT and 65·8% for Rd18. The risk of progression or death was reduced by 39% with Rd continuous versus MPT and by 35% with Rd continuous versus Rd18. Rd continuous improved the 3-year survival rate compared with MPT (70·2% vs. 56·4%) and Rd18 (58·1%). Common grade 3/4 adverse events in the Rd continuous and MPT arms were neutropenia (25·0% vs. 43·6%), infection (19·4% vs. 28·2%) and anaemia (19·4% vs. 15·4%), respectively. Thromboembolic event rates were low, and no second primary malignancies were observed. Rd continuous is safe and effective in transplant-ineligible Asian patients with NDMM. © 2017 The Authors. British Journal of Haematology Published by John Wiley & Sons Ltd.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区血液学

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区血液学

JCR分区：

出版当年[2017]版：

Q1 HEMATOLOGY

最新[2023]版：

Q1 HEMATOLOGY

影响因子： 5.1 最新[2023版] 5.7 最新五年平均 5.128 出版当年[2017版] 5.33 出版当年五年平均 5.67 出版前一年[2016版] 5.206 出版后一年[2018版]

第一作者：

第一作者机构： [1]Peking University People’s Hospital, Beijing, China,

通讯作者：

通讯机构： [18]Service des Maladies du Sang, Hoˆpital Claude Huriez, Lille, France [*1]Service des Maladies du Sang, CHRU rue Michel Polonovski, 59037 Lille, France.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.

文献详情

相关文献